ClinicalTrials.gg
Not yet recruitingNCT06725537CA209-1529Updated Jan 15, 2025

Comprehensive Demographics and Clinical Profile of NSCLC Patients

An observational study in Lung Cancer Non Small Cell, sponsored by D'Or Institute for Research and Education. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-15.

Sponsored by D'Or Institute for Research and Education · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

Advances in the treatment of non-small cell lung cancer in the last decade have been significant. Currently, there are several first-line therapeutic options. The molecular biology of the disease, biomarkers and the patient's clinical characteristics can assist in decision making. The study in question aims to retrospectively evaluate the patterns of choice in the first line treatment of metastatic non-small cell lung cancer without driver mutations, from 2019 to 2022 in 7 centers in Brazil.

Read the detailed description

Lung cancer is the most incident neoplasm in the world (considering both sexes), with 2.4 million (12.4%) new cases per year, based on estimates from the Global Cancer Observatory (Globocan) in 2022 (1). Non-small cell histology (NSCLC) is the most common and represents around 76% of lung cancer cases (2). Despite improvements in its prevention and diagnosis, a large proportion of patients are diagnosed in the advanced stage of the disease (57%) (3) and some of those diagnosed with localized disease will experience recurrence of the neoplasm. In this sense, choosing the most appropriate first-line treatment is necessary.

The last decade has been marked by advances in the treatment of lung cancer. Regarding metastatic non-small cell lung cancer without target mutation, the inclusion of immunotherapy in the therapeutic arsenal has led to a significant increase in survival rates (2). Currently, with the exception of a few patients given specific contraindications, an immunological check point inhibitor (ICI) will be present in the first-line treatment of this group (4). The current challenge is choosing the best treatment approach for each patient.

The use of ICI in the first line can be used as monotherapy or combination therapy. In 2016, the KEYNOTE-024 study was published in NEJM, a pioneer in this scenario, which evaluated the use of Pembrolizumab monotherapy in patients with a TPS score ≥50% (5). It was a positive study for its primary outcome of progression-free survival (PFS), with a median PFS of 10.3 months for the group that received Immunotherapy versus 6.7 months for the group that received chemotherapy (CT) (HR 0.5; 0.37 - 0.68 ). It also demonstrated a significant gain in overall survival (OS), with 5-year follow-up reaffirmation - median OS 26.3 months for Pembrolizumab versus 13.4 months for CT (HR 0.62; 0.48 - 0.81) (6). Five years after first publication of KN-024, the EMPOWER Lung-01 study was published in the Lancet (7). He evaluated the use of Cemiplimab in the same population and also obtained positive results in relation to OS (26.1 months ICI arm versus 13.3 months in the CT arm - HR 0.57; 0.46 - 0.71) (8) and PFS.

In relation to patients with low expression (1-49%) or without PD-L1 expression (negative), the combination of immunotherapy and chemotherapy appears to be a good treatment strategy. The KEYNOTE-189 study, published in NEJM in 2018, evaluated the use of Pembrolizumab associated with doublet chemotherapy (Carboplatin or Cisplatin + Pemetrexed) in patients with lung adenocarcinoma without target alteration (EGFR or ALK) regardless of PD-L1 expression (9). Their results show a survival benefit with the use of the combination with ICI and updated data on 5-year OS maintain this gain (19.4% versus 11.3%) (10). In the same year, the KEYNOTE-407 study evaluated the use of Pembrolizumab in combination with CT in patients with squamous histology. Similarly, it demonstrated a survival benefit (11). In its most recent update, the 5-year OS data maintains benefit for the ICI combination arm, with a 29% reduction in the risk of death (12).

In this same subgroup, other medications were evaluated. The IMPOWER-150 study evaluated the use of Atezolizumab in combination with CT, with and without the VEFG inhibitor (Bevacizumab) (13). It included patients with metastatic lung adenocarcinoma and included patients with EGFR and ALK mutations, but only in a small proportion. The study met its coprimary endpoints of PFS and OS, with a median OS of 19.0 months for the ICI+CT+Bevacizumab combination versus 14.7 months for the CT+Bevacizumab arm (14).

Finally, the ICI combination was also evaluated. Three studies are worth highlighting. The first of them, CheckMate-227, evaluated the use of Ipilimumab and Nivolumab, without the addition of CT (15). There was an OS benefit from the combination, regardless of PD-L1 expression, with 6-year OS of 22% in the PD-L1 positive population and 16% in the negative one (16). The second, CheckMate-9LA evaluated the use of Ipilimumab and Nivolumab, associated with two CT cycles. The scheme led to a benefit in OS, with a reduction in the risk of death by 27% in five-year data update (17). Similarly, the POSEIDON study evaluated the use of Durvalumab and Tremelimumab associated with CT, leading to a benefit in OS from the combination (18).

When confronted with numerous options, oncologists seek unique characteristics and biomarkers to inform their decisions. They consider patient factors such as age, comorbidities, and performance status. Regarding tumor patterns, details like histology, the location of metastatic disease (CNS vs. non-CNS), and PD-L1 expression are also crucial in guiding their choices.

In relation to patients with actionable target mutations, standard first-line management may differ from that previously explored. Therefore, it is extremely important to investigate molecular biology, especially in non-squamous histology and in non-smoking patients. The evaluation of the EGFR and ALK genes is essential, as well as the BRAF, RAS, RET, MET, NTRK, HER2 and ROS1 genes.

In the current scenario, there are several treatment options targeting specific actionable mutations approved in Brazil. Testing for these key mutations is widely available, and assessing the quality, reliability, and turnaround time of the test, as well as the molecular alterations considered by the physician when choosing the first line and sequencing the treatment, is important.

In summary first-line treatment of NSCLC has peculiarities and molecular evaluation is mandatory. Several treatment regimens have demonstrated benefit in OS, but they have not been directly compared (15). Given the options presented, the current challenge is choosing the best treatment approach for each patient (16). The search for biomarkers that predict response, which help in decision making, is tireless. Currently, this definition is made by specialist oncologists, who use the data presented so far to make the choice. Subgroup assessments in each study, the toxicity profile and dosage are points taken into consideration. Thus, the identification of data that assists doctors in this decision-making becomes attractive.

02

Conditions studied

  • Lung Cancer Non Small Cell

Keywords

  • neoplasia
  • lung
  • metastasis
  • first line treatment
03

In context

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's planned enrollment of 500 is above the median of 160 across 1,151 observational studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

D'Or Institute for Research and Education is the lead sponsor of 42 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with a histological diagnosis of advanced non-small cell lung cancer, over 18 years of age

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 18 years old;
  • Histological diagnosis of advanced non-small cell cancer;
  • Clinical and demographic data available in medical records;

Exclusion criteria

Exclusion Criteria:

  • Patients with localized disease that can be treated locally;
  • Non-epithelial histology;
  • small cell carcinoma
  • neuroendocrine tumor
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. treatment regimen decision option one

    immunotherapy versus chemotherapy, this outcome will be evaluated based on data from medical records and available laboratory results

    Time frame: In 30 days

  2. treatment regimen decision option two

    dual immunotherapy, this outcome will be evaluated based on data from medical records and available laboratory results

    Time frame: In 30 days

Secondary outcomes

  1. Survival analysis

    Survival will be analyzed secondarily, using the variable time to death

    Time frame: In 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2025; primary completion for Mar 2025, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2024
First posted
Dec 10, 2024
StartEst.
Jan 20, 2025
Primary completionEst.
Mar 1, 2025
CompletionEst.
Aug 1, 2025
Last update
Jan 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06725537
Lead sponsor
D'Or Institute for Research and Education
Responsible party
Sponsor
First posted
Dec 10, 2024
Start date
Jan 20, 2025 (estimated)
Primary completion
Mar 1, 2025 (estimated)
Completion
Aug 1, 2025 (estimated)
Last update
Jan 15, 2025

Study contacts

Sofia V Mendes, MD
Contact
sofiavidaurre@hotmail.com
+55 (21) 999165250 ext. 5250
Sofia V Mendes, MD
principal investigator · Instituto D'Or de Pesquisa e Ensino

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion